Global Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities (Chemotherapy, Combination Therapies, Immunotherapy), Drug Type (Atezolizumab, Durvalumab, Etoposide), Route of Administration, Distribution Channel - Forecast 2024-2030- Product Image

Sale

Global Extensive Stage Small Cell Lung Cancer Market by Treatment Modalities (Chemotherapy, Combination Therapies, Immunotherapy), Drug Type (Atezolizumab, Durvalumab, Etoposide), Route of Administration, Distribution Channel - Forecast 2024-2030

Report
196 Pages
March 2024
Region: Global
360iResearch™
ID: 5924699

UP TO €846EUR$875USD£727GBP OFF until Dec 31^st 2024

The Extensive Stage Small Cell Lung Cancer Market size was estimated at USD 4.75 billion in 2023, USD 5.40 billion in 2024, and is expected to grow at a CAGR of 12.63% to reach USD 10.92 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Extensive Stage Small Cell Lung Cancer Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Extensive Stage Small Cell Lung Cancer Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Extensive Stage Small Cell Lung Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly & Company Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson & Johnson Services, Inc., Merck KGaA, Nektar Therapeutics, Novartis AG, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd.

Market Segmentation & Coverage

This research report categorizes the Extensive Stage Small Cell Lung Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Modalities
- Chemotherapy
- Combination Therapies
- Immunotherapy
- Radiation Therapy
- Targeted Therapies
Drug Type
- Atezolizumab
- Durvalumab
- Etoposide
- Lurbinectedin
- Methotrexate
- Pembrolizumab
- Topotecan
Route of Administration
- Oral
- Parenteral
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Extensive Stage Small Cell Lung Cancer Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Extensive Stage Small Cell Lung Cancer Market?
What are the technology trends and regulatory frameworks in the Extensive Stage Small Cell Lung Cancer Market?
What is the market share of the leading vendors in the Extensive Stage Small Cell Lung Cancer Market?
Which modes and strategic moves are suitable for entering the Extensive Stage Small Cell Lung Cancer Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Extensive Stage Small Cell Lung Cancer Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in prevalence of extensive stage small cell lung cancer across the globe
5.1.1.2. Growing awareness regarding enhanced health care
5.1.1.3. Rising government initiatives for extensive stage small cell lung cancer treatment
5.1.2. Restraints
5.1.2.1. Huge availability of the generic drugs
5.1.3. Opportunities
5.1.3.1. Increasing funding in the field of research and development of new treatment
5.1.3.2. Technological advancement in the extensive stage small cell lung cancer screening procedures
5.1.4. Challenges
5.1.4.1. Risk of side effects of radiation and chemotherapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Extensive Stage Small Cell Lung Cancer Market, by Treatment Modalities

6.1. Introduction
6.2. Chemotherapy
6.3. Combination Therapies
6.4. Immunotherapy
6.5. Radiation Therapy
6.6. Targeted Therapies

7. Extensive Stage Small Cell Lung Cancer Market, by Drug Type

7.1. Introduction
7.2. Atezolizumab
7.3. Durvalumab
7.4. Etoposide
7.5. Lurbinectedin
7.6. Methotrexate
7.7. Pembrolizumab
7.8. Topotecan

8. Extensive Stage Small Cell Lung Cancer Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Extensive Stage Small Cell Lung Cancer Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies

10. Americas Extensive Stage Small Cell Lung Cancer Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Extensive Stage Small Cell Lung Cancer Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Extensive Stage Small Cell Lung Cancer Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
14.1.1. AbbVie Inc.
14.1.2. Amgen Inc.
14.1.3. Astellas Pharma Inc.
14.1.4. AstraZeneca PLC
14.1.5. Boehringer Ingelheim GmbH
14.1.6. Bristol Myers Squibb Company
14.1.7. Celgene Corporation
14.1.8. Daiichi Sankyo Company, Limited
14.1.9. Eisai Co., Ltd.
14.1.10. Eli Lilly & Company Ltd.
14.1.11. Exelixis, Inc.
14.1.12. F. Hoffmann-La Roche AG
14.1.13. Genentech, Inc.
14.1.14. Gilead Sciences, Inc.
14.1.15. GlaxoSmithKline PLC
14.1.16. Incyte Corporation
14.1.17. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
14.1.18. Johnson & Johnson Services, Inc.
14.1.19. Merck KGaA
14.1.20. Nektar Therapeutics
14.1.21. Novartis AG
14.1.22. Pfizer, Inc.
14.1.23. Sanofi S.A.
14.1.24. Takeda Pharmaceutical Co. Ltd.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing

List of Figures

FIGURE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET RESEARCH PROCESS
FIGURE 2. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2023 VS 2030
FIGURE 3. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET DYNAMICS
FIGURE 7. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2030 (%)
FIGURE 8. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 10. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 6. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 12. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY LURBINECTEDIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TOPOTECAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 40. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 41. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 44. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 62. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 66. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 74. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 98. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 111. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 115. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 119. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 123. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 127. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 135. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 147. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 151. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 155. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 156. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 171. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 183. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 184. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 195. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
TABLE 196. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Bristol Myers Squibb Company
Celgene Corporation
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Eli Lilly & Company Ltd.
Exelixis, Inc.
F. Hoffmann-La Roche AG
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Incyte Corporation
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Johnson & Johnson Services, Inc.
Merck KGaA
Nektar Therapeutics
Novartis AG
Pfizer, Inc.
Sanofi S.A.
Takeda Pharmaceutical Co. Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	196
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 5.4 Billion
Forecasted Market Value ( USD ) by 2030	$ 10.92 Billion
Compound Annual Growth Rate	12.6%
Regions Covered	Global
No. of Companies Mentioned	24

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3262EUR$3,374USD£2,804GBP €3624EUR$3,749USD£3,115GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4132EUR$4,274USD£3,551GBP €4591EUR$4,749USD£3,946GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5002EUR$5,174USD£4,299GBP €5558EUR$5,749USD£4,777GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5872EUR$6,074USD£5,047GBP €6524EUR$6,749USD£5,608GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7612EUR$7,874USD£6,543GBP €8458EUR$8,749USD£7,270GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Immune Checkpoint Inhibitors for Lung Cancer Market by Products (Atezolizumab, Durvalumab, Nivolumab), Type (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End-Users - Forecast 2024-2030

Etoposide Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

Etoposide (CAS 33419-42-0) Global Market Research Report 2024

Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024

Non-small cell lung cancer (NSCLC) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034